Baxter announces FDA approval of ADVATE with BAXJECT III reconstitution system
Baxter announced the FDA has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]). ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system. Baxter has also filed for approval of ADVATE with BAXJECT III system in Europe. April 23, 2014